Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 3, 2004, Pages 139-146

  Erkens, Joëlle A ^a,b   Klungel, Olaf H ^a   Stolk, Ronald P ^b   Spoelstra, José A ^a,b   Grobbee, Diederick E ^b   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Amputation; Antihypertensive drugs; Thiazide; Type 2 diabetes mellitus

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIGOUT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE DERIVATIVE; LOOP DIURETIC AGENT; NITRATE; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT;

AGE; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; LEG AMPUTATION; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL INFORMATION SYSTEM; MONOTHERAPY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PHARMACY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TIME;

AGED; AMPUTATION; ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; LOWER EXTREMITY; MALE; PEPTIDYL-DIPEPTIDASE A; RISK; SODIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS;

EID: 1542411436     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.932     Document Type: Article

References (48)

1. van Houtum WH, Lavery LA, Harkless LB. The impact of diabetes-related lower-extremity amputations in The Netherlands. J Diabetes Complications 1996; 10: 325-330.
2. Humphrey AR, Dowse GK, Thoma K, Zimmet PZ. Diabetes and nontraumatic lower extremity amputations: incidence, risk factors, and prevention - a 12-year follow-up study in Nauru. Diabetes Care 1996; 19: 710-714.
3. Moss SE, Klein R, Klein BE. The 14-year incidence of lower-extremity amputations in a diabetic population: the Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care 1999; 22: 951-959.
4. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 1990; 13: 513-521.
5. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-162.
6. Adler AI, Boyko EJ, Ahroni JH, Smith DG. Lower-extremity amputation in diabetes: the independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 1999; 22: 1029-1035.
7. Lee JS, Lu M, Lee VS, Russell D, Bahr C, Lee ET. Lower-extremity amputation: incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study. Diabetes 1993; 42: 876-882.
8. Mayfield JA, Reiber GE, Nelson RG, Greene T. A foot risk classification system to predict diabetic amputation in Pima Indians. Diabetes Care 1996; 19: 704-709.
9. Hamalainen H, Ronnemaa T, Halonen JP, Toikka T. Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: a population-based 7-year follow-up study. J Intern Med 1999; 246: 97-103.
10. Selby JV, Zhang D. Risk factors for lower extremity amputation in persons with diabetes. Diabetes Care 1995; 18: 509-516.
11. UK Prospective Diabetes Study Group (UKPDS 38). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 317: 703-713.
12. Nicolucci A, Cavaliere D, Scorpiglione N, et al. A comprehensive assessment of the avoidability of long-term complications of diabetes: a case-control study. SID-AMD Italian Study Group For The Implementation Of The St. Vincent Declaration. Diabetes Care 1996; 19: 927-933.
13. Nelson RG, Gohdes DM, Everhart JE, et al. Lower-extremity amputations in NIDDM: 12-yr follow-up study in Pima Indians. Diabetes Care 1988; 11: 8-16.
14. Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus: a case-control study. Ann Intern Med 1992; 117: 97-105.
15. Lievre M, Gueyffier F, Ekbom T, et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients: results from a meta-analysis. The INDANA Steering Committee. Diabetes Care 2000; 23(Suppl. 2): B65-71.
16. UK Prospective Diabetes Study Group (UKPDS 39). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 317: 713-720.
17. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-1964.
18. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-1892.
19. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
20. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
21. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.
22. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
23. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-140.
24. SIG Health Care Information. Classification of Performances. SIG Health Care Information: Utrecht, 1994.
25. Siscovick DS, Schwartz SM, Caps M, Wang SP, Grayston JT. Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology. J Infect Dis 2000; 181(Suppl. 3): S417-S420.
26. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J 1995; 311: 293-295.
27. EGRET for Windows. Cambridge MA, 1999.
28. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
29. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995; 33: 783-795.
30. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373-1379.
31. Lithell HO, Andersson PE. Antihypertensive treatment in insulin resistant patients. Hypertens Res 1996; 19(Suppl. 1): S75-S79.
32. Flamenbaum W. Metabolic consequences of antihypertensive therapy. Ann Intern Med 1983; 98: 875-880.
33. Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ED. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999; 159: 551-558.
34. Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J 1983; 106: 245-251.
35. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-921.
36. Nadler JL, Malayan S, Luong H, Shaw S, Natarajan RD, Rude RK. Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care 1992; 15: 835-841.
37. Ames RP. Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: possible alternative drug therapies. Am J Cardiol 1983; 51: 632-638.
38. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-892.
39. van Ballegooie E, van Everdingen JJ. CBO guidelines on diagnosis, treatment, and prevention of complication in diabetes mellitus: retinopathy, foot ulcers, nephropathy and cardiovascular diseases. Dutch Institute for Quality Assurance. Ned Tijdschr Geneeskd 2000; 144: 413-418.
40. ALLHAT Collaborative Research Group(ALLHAT). Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 2000; 283: 1967-1975.
41. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 2002; 288: 2981-2997.
42. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-372.
43. Makin A, Lip GY, Silverman S, Beevers DG. Peripheral vascular disease and hypertension: a forgotten association? J Hum Hypertens 2001; 15: 447-454.
44. Heintzen MP, Strauer BE. Peripheral vascular effects of beta-blockers. Eur Heart J 1994; 15(Suppl. C): 2-7.
45. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 1998; 21: 42-48.
46. Bouter KP, Storm AJ, de Groot RR, Uitslager R, Erkelens DW, Diepersloot RJ. The diabetic foot in Dutch hospitals: epidemiological features and clinical outcome. Eur J Med 1993; 2: 215-218.
47. Calle-Pascual AL, Garcia-Torre N, Moraga I, et al. Epidemiology of nontraumatic lower-extremity amputation in area 7, madrid, between 1989 and 1999: a population-based study. Diabetes Care 2001; 24: 1686-1689.
48. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138: 593-602.